The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000668303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
7/05/2026
Date registered
Help: Date registered
4/06/2026
Date last updated
Help: Date last updated
7/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Orally Administered RT-312 in Healthy Participants
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, Single and Multiple Ascending Doses (SAD/MAD) Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Orally Administered RT-312
Additional trial identifiers [1] 317187 0
Protocol RT-312-101
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Autosomal dominant polycystic kidney disease 341767 0
Condition category
Condition code
Renal and Urogenital 337844 337844 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a two-part, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RT-312 following single (Part 1) and multiple (Part 2) ascending dose administration in healthy participants. Part 1 will also explore the effect of food on a single oral dose of RT-312 (Food Effect cohort). Up to 80 participants between 18 and 45 years of age at the time of providing informed consent, will be enrolled in this study across the two parts.

RT-312 will be administered as an oral tablet (yellow, film-coated, immediate release tablet in 10 mg or 30 mg strength). Placebo will be administered as an oral (lactose monohydrate and microcellulose) tablet, matched in appearance to RT-312.

There will be up to 7 groups (cohorts) of 8 participants (2 placebo and 6 active per cohort) in Part 1 of the study, with planned doses of 10 mg, 30 mg, 60 mg, 90 mg, 120 mg, 180 mg, and 240 mg of RT-312 or placebo administered once. One Part 1 cohort (planned at 90 mg) will receive a second dose of RT-312 or placebo administered with a standard breakfast at least 7 days after the first dose. Breakfast will be provided by the research team and may be comprised of toast, bacon, eggs, or similar items.

There will be up to 3 cohorts of 8 participants (2 placebo and 6 active per cohort) in Part 2 of the study, with planned doses of 60 mg, 90 mg, and 120 mg of RT-312 or placebo administered once daily for 7 days. Dose levels may be adjusted by the Safety Review Committee depending on emerging data from earlier cohorts.

Adherence to the intervention protocol will be confirmed via mouth checks and documentation by site personnel dispensing and administering the investigational product.
Intervention code [1] 333955 0
Treatment: Drugs
Description of the comparator or control
Placebo administered as an oral (lactose monohydrate and microcellulose) tablet, matched in appearance to RT-312
Control group
Placebo

Outcomes
Primary outcome [1] 345303 0
Safety and tolerability of single and multiple doses of RT-312. This will be assessed as a composite outcome.
Timepoint [1] 345303 0
TEAEs will be assessed throughout the study. In Part 1, vital signs will be assessed at Screening, Day -1, Day 1 at pre-dose,0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose, Day 2, Day 3, and Day 8. ECGs will be performed at Screening, Day -1, Day 1 at 60 minutes, 40 minutes and 20 minutes pre-dose, and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose, Day 2, Day 3, and Day 8. Physical examinations will be performed at Screening, Day -1, Day 2, Day 3, and Day 8. Laboratory safety tests will be completed at Screening, Day -1, Day 2, Day 3, and Day 8. Water intake will be assessed for the first 24 hours post-dose. In Part 2, vital signs will be assessed at Screening, Day -1, Day 1 at pre-dose,0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose, Day 2-6 at pre-dose and 3, 4, and 6 hours post-dose, Day 7 at pre-dose, 2, 3, 4, and 6 hours post-dose, Day 8, Day 9, and Day 14. ECGs will be performed at Screening, Day -1, Day 1 at pre-dose, 2 and 4 hours post-dose, Day 2, 4, and 6 pre-dose, Day 7 at pre-dose, 2 and 4 hours post-dose, Day 8, Day 9, and Day 14. Physical examinations will be performed at Screening, Day -1, as required from Days 1-8, and on Day 9 and Day 16. Laboratory safety tests will be completed at Screening, Day -1, Day 2, Day 4, Day 6, Day 8, Day 9, and Day 14. Water intake will be assessed each day from Day 1 to Day 8.
Secondary outcome [1] 461224 0
Pharmacokinetic (PK) concentration and parameters in plasma and urine following single doses of RT-312
Timepoint [1] 461224 0
Blood PK sampling will occur on Day 1 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose, Day 2, Day 3, and Day 8. Urine PK sampling will be performed from bulk urine collection at 0-4, 4-8, 8-12, and 12-24 hours post dose.
Secondary outcome [2] 461225 0
Pharmacodynamic (PD) profile in serum and urine following single doses of RT-312.
Timepoint [2] 461225 0
Blood PD sampling will occur on Day 1 at pre-dose and 4, 8, and 12 hours post-dose, Day 2, Day 3, and Day 8. Urine PD sampling will be performed from bulk urine collection at 0-4, 4-8, 8-12, and 12-24 hours post dose.
Secondary outcome [3] 461226 0
Pharmacokinetic (PK) concentration and parameters in plasma and urine following a single dose of RT-312 administered with food.
Timepoint [3] 461226 0
PK sampling will be performed at the following timepoints in the Food Effect cohort: Blood PK sampling will occur on Day 1 at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose, Day 2, Day 3, and Day 8. Urine PK sampling will be performed from bulk urine collection at 0-4, 4-8, 8-12, and 12-24 hours post dose.
Secondary outcome [4] 461227 0
Pharmacodynamic (PD) profile following a single dose of RT-312 administered with food.
Timepoint [4] 461227 0
PD sampling will be performed at the following timepoints in the Food Effect cohort: Blood PD sampling will occur on Day 1 at pre-dose and 4, 8, and 12 hours post-dose, Day 2, Day 3, and Day 8. Urine PD sampling will be performed from bulk urine collection at 0-4, 4-8, 8-12, and 12-24 hours post dose.
Secondary outcome [5] 461228 0
Pharmacokinetic (PK) concentration and parameters in plasma and urine following multiple doses of RT-312
Timepoint [5] 461228 0
Blood PK sampling will occur on Day 1 pre-dose and 0.5, 1, 2, 3 4, 6, 8, and 12 hours post-dose, Day 2-6 pre-dose, Day 7 pre-dose and 0.5, 1, 2, 3 4, 6, 8, and 12 hours post-dose, Day 8, Day 9, and Day 14. Urine PK sampling will be performed from bulk urine collection on Day 1 and 7 at 0-4, 4-8, 8-12, and 12-24 hours post dose, and on Days 2-6 at 0-24 hours.
Secondary outcome [6] 461742 0
Pharmacodynamic (PD) profile in serum and urine following multiple doses of RT-312.
Timepoint [6] 461742 0
Blood PD sampling will occur on Day 1 pre-dose and 4, 8, and 12 hours post-dose, Day 2-6 pre-dose, Day 7 pre-dose and 0.5, 1, 2, 3 4, 6, 8, and 12 hours post-dose, Day 8, Day 9, and Day 14. Urine PD sampling will be performed from bulk urine collection on Day 1 and 7 at 0-4, 4-8, 8-12, and 12-24 hours post dose, and on Days 2-6 at 0-24 hours.

Eligibility
Key inclusion criteria
- Healthy male or female participants, between the ages of 18 and 45 years inclusive, at the time of signing the informed consent
- Medically healthy (in the opinion of the Investigator or delegate), as determined by pre-study medical history, and without clinically significant abnormalities in physical examination, vital signs, ECG or laboratory safety tests
- Body weight within 50 to 120 kg (inclusive) and BMI within the range 18 to 32 kg/m2 (inclusive)
- Willing and able to adhere to study restrictions, including contraception requirements
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- Evidence or clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, malignancies, or drug hypersensitivity as determined by the Investigator. Includes genetic immunodeficiency or family history of genetic immunodeficiency, dysphagia or any history of gastrointestinal diseases that affect drug absorption or have undergone operations that affect drug absorption
- Recent hospital admission or major surgery within 3 months prior to Screening, or elective surgery within 4 weeks prior to study intervention administration
- Any history of organ or bone marrow transplant
- History of prescription or illicit drug abuse or alcohol abuse within 6 months prior to Screening, or positive alcohol or drug test at Screening or admission
- Evidence of SARS-CoV-2 infection at time of Screening or admission
- Positive serology test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Major clinical infections or active infection with herpes simplex, herpes zoster, or varicella within 3 months prior to Screening, or any symptoms of infection (excluding foot fungal infection) within 7 days prior to Screening
- Donated or lost >500 ml of blood in the previous 30 days prior to Screening
- Any condition or finding that in the opinion of the Investigator or designee would put the individual or study conduct at risk if the individual were to participate in the study
- Any liver function panel analyte value above upper limit of normal
- Taken any prescription medications (excluding contraceptives) within 14 days or 5 half-lives (whichever is longer) of the first dose of study intervention.
- Received live vaccines or attenuated vaccines within 1 month before dosing.
- Used over the counter (OTC) medication, herbal medication and dietary supplements (including St John’s Wort) within 7 days or 5 half-lives prior to dosing, whichever is later. Occasional paracetamol (up to 1000 mg per day) is allowed until time of admission
- Received any other experimental therapy including device or an investigational agent within 30 days or 5 half-lives (whichever is longer) prior to first study intervention administration
- Inability to attend all the study visits or comply with study procedures (including smoking, caffeine, and dietary restrictions during admission)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be assigned a randomisation number, which corresponds to a study treatment (RT-312 or placebo), in accordance with the randomisation schedule. The randomisation schedule will be prepared by unblinded statistician(s) and will be maintained under controlled access. Blinded study staff will not have access to the randomisation schedule until after database lock.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Allocation to RT-312 or placebo will be performed using a block randomisation algorithm.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis
Listings and tabulation of safety and efficacy variables
Pharmacokinetic and pharmacodynamic analysis and modeling to estimate and visualize standard parameters
Sample size is based on customary practice in Phase 1 clinical studies.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29467 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 45785 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 321770 0
Commercial sector/Industry
Name [1] 321770 0
Retex AU Pty Ltd
Country [1] 321770 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Retex AU Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324611 0
None
Name [1] 324611 0
Address [1] 324611 0
Country [1] 324611 0
Other collaborator category [1] 283926 0
Commercial sector/Industry
Name [1] 283926 0
Emerald Clinical Trials Pty Ltd
Address [1] 283926 0
Country [1] 283926 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320313 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320313 0
Ethics committee country [1] 320313 0
Australia
Date submitted for ethics approval [1] 320313 0
27/04/2026
Approval date [1] 320313 0
01/06/2026
Ethics approval number [1] 320313 0
304-26

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150054 0
Dr Aarthy Joseph
Address 150054 0
Nucleus Network Pty Ltd, Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, Victoria, 3004
Country 150054 0
Australia
Phone 150054 0
+61385939801
Fax 150054 0
Email 150054 0
Contact person for public queries
Name 150055 0
Nucleus Network Melbourne
Address 150055 0
Nucleus Network Melbourne, Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, Victoria, 3004
Country 150055 0
Australia
Phone 150055 0
+611800243733
Fax 150055 0
Email 150055 0
Contact person for scientific queries
Name 150056 0
Li Yi
Address 150056 0
Retex AU Pty Ltd, U15/7 Sefton Rd, Thornleigh, NSW 2120
Country 150056 0
Australia
Phone 150056 0
+61493494739
Fax 150056 0
Email 150056 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: No individual data will be released in any form.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.